Literature DB >> 20039008

The beneficial effects of C-Peptide on diabetic polyneuropathy.

Hideki Kamiya1, Weixian Zhang, Anders A F Sima.   

Abstract

Diabetic polyneuropathy (DPN) is a common complication in diabetes. At present, there is no adequate treatment, and DPN is often debilitating for patients. It is a heterogeneous disorder and differs in type 1 and type 2 diabetes. An important underlying factor in type 1 DPN is insulin deficiency. Proinsulin C-peptide is a critical element in the cascade of events. In this review, we describe the physiological role of C-peptide and how it provides an insulin-like signaling function. Such effects translate into beneficial outcomes in early metabolic perturbations of neural Na+/K+-ATPase and nitric oxide (NO) with subsequent preventive effects on early nerve dysfunction. Further corrective consequences resulting from this signaling cascade have beneficial effects on gene regulation of early gene responses, neurotrophic factors, their receptors, and the insulin receptor itself. This may lead to preventive and corrective results to nerve fiber degeneration and loss, as well as, promotion of nerve fiber regeneration with respect to sensory somatic fibers and small nociceptive nerve fibers. A characteristic abnormality of type 1 DPN is nodal and paranodal degeneration with severe consequences for myelinated fiber function. This review deals in detail with the underlying insulin-deficiency-related molecular changes and their correction by C-peptide. Based on these observations, it is evident that continuous maintenance of insulin-like actions by C-peptide is needed in peripheral nerve to minimize the sequences of metabolic and molecular abnormalities, thereby ameliorating neuropathic complications. There is now ample evidence demonstrating that C-peptide replacement in type 1 diabetes promotes insulin action and signaling activities in a more enhanced, prolonged, and continuous fashion than does insulin alone. It is therefore necessary to replace C-peptide to physiological levels in diabetic patients. This will have substantial beneficial effects on type 1 DPN.

Entities:  

Year:  2009        PMID: 20039008      PMCID: PMC2827271          DOI: 10.1900/RDS.2009.6.187

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN: 1613-6071


  112 in total

Review 1.  Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials.

Authors:  D Ziegler; M Reljanovic; H Mehnert; F A Gries
Journal:  Exp Clin Endocrinol Diabetes       Date:  1999       Impact factor: 2.949

2.  A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats.

Authors:  A A Sima; W Zhang; G Xu; K Sugimoto; D Guberski; M A Yorek
Journal:  Diabetologia       Date:  2000-06       Impact factor: 10.122

3.  C-peptide improves autonomic nerve function in IDDM patients.

Authors:  B L Johansson; K Borg; E Fernqvist-Forbes; T Odergren; S Remahl; J Wahren
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

4.  C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin.

Authors:  M E Jensen; E J Messina
Journal:  Am J Physiol       Date:  1999-04

5.  Dynamic changes of neuroskeletal proteins in DRGs underlie impaired axonal maturation and progressive axonal degeneration in type 1 diabetes.

Authors:  Hideki Kamiya; Weixian Zhang; Anders A F Sima
Journal:  Exp Diabetes Res       Date:  2009-10-12

6.  Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter.

Authors:  J A Meyer; J M Froelich; G E Reid; W K A Karunarathne; D M Spence
Journal:  Diabetologia       Date:  2007-10-27       Impact factor: 10.122

7.  Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.

Authors:  George J Francis; Jose A Martinez; Wei Q Liu; Kevin Xu; Amit Ayer; Jared Fine; Ursula I Tuor; Gordon Glazner; Leah R Hanson; William H Frey; Cory Toth
Journal:  Brain       Date:  2008-11-16       Impact factor: 13.501

8.  Molecular effects of C-Peptide in microvascular blood flow regulation.

Authors:  Thomas Forst; Thomas Hach; Thomas Kunt; Matthias M Weber; Andreas Pfützner
Journal:  Rev Diabet Stud       Date:  2009-11-10

9.  Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-Peptide.

Authors:  Anders A F Sima; Weixian Zhang; Otto Muzik; Christian W Kreipke; José A Rafols; William H Hoffman
Journal:  Rev Diabet Stud       Date:  2009-11-10

10.  Elevated triglycerides correlate with progression of diabetic neuropathy.

Authors:  Timothy D Wiggin; Kelli A Sullivan; Rodica Pop-Busui; Antonino Amato; Anders A F Sima; Eva L Feldman
Journal:  Diabetes       Date:  2009-05-01       Impact factor: 9.461

View more
  6 in total

1.  Clinical utility of insulin and insulin analogs.

Authors:  Ahter D Sanlioglu; Hasan Ali Altunbas; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Islets       Date:  2013-03-01       Impact factor: 2.694

2.  Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-Peptide.

Authors:  Anders A F Sima; Weixian Zhang; Otto Muzik; Christian W Kreipke; José A Rafols; William H Hoffman
Journal:  Rev Diabet Stud       Date:  2009-11-10

3.  Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes.

Authors:  Fulya Erendor; Yunus Emre Eksi; Elif Ozgecan Sahin; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

4.  C-peptide is independent associated with diabetic peripheral neuropathy: a community-based study.

Authors:  Xiaona Qiao; Hangping Zheng; Shuo Zhang; Siying Liu; Qian Xiong; Fei Mao; Zhaoyun Zhang; Jie Wen; Hongying Ye; Yiming Li; Bin Lu
Journal:  Diabetol Metab Syndr       Date:  2017-02-13       Impact factor: 3.320

5.  Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients.

Authors:  Hye-Jin Yoon; Youn-Zoo Cho; Ji-Young Kim; Byung-Joon Kim; Keun-Young Park; Gwan-Pyo Koh; Dae-Ho Lee; Dong-Mee Lim
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

6.  Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes.

Authors:  Xiaona Qiao; Shuo Zhang; Weiwei Zhao; Hongying Ye; Yehong Yang; Zhaoyun Zhang; Qing Miao; Renming Hu; Yiming Li; Bin Lu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.